PLx Pharma

PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PLx Pharma is a pharmaceutical company that develops and commercializes non-steroidal anti-inflammatory drugs (NSAIDs) for prescription and over-the-counter markets in the United States. The company offers PL2200 Aspirin, a molecular complex of aspirin and phosphatidylcholine; and PL1100/1200 Ibuprofen, which are oral drug products containing a molecular complex of ibuprofen and phosphatidylcholine.

SPARTA, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ and VAZALORE®, an FDA-approved liquid-filled aspirin capsule, available in 81 mg and 325 mg doses. The Company today announced that it entered into a stalking horse asset purchase agreement (the “APA”) with PLx Acquisition Company, LLC, a wholly-owned subsidiary of Greenwood Brands, LLC (“Buyer”), to acquire substantially all of the Company's assets (the “Sale”).

PLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE® and Substantially All of its Assets

PLx Pharma (NASDAQ: PLXP ) stock continues to fall on Wednesday as the company gets closer to being delisted from the Nasdaq Exchange . An update from PLx Pharma revealed that the Nasdaq is not giving it another 180-day period to regain compliance with listing rules.

Why Is PLx Pharma (PLXP) Stock Down 32% Today?

SPARTA, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company had previously announced that on October 3, 2022, it was notified by the Listing Qualifications Department (the “Listing Qualifications Department”) of the Nasdaq Stock Market LLC (“Nasdaq”) that the Listing Qualifications Department has determined to delist the Company's securities from Nasdaq, citing that for a period of 30 consecutive business days, the bid price of its common stock had closed below the minimum of $1.00 per share required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until April 3, 2023, to regain compliance with the minimum bid requirement. On April 4, 2023, the Company received notice from Nasdaq (the “April Notice”) indicating that the Company had not regained compliance with the Rule and is not eligible for a second 180-day period. The April Notice also stated that the Company had not yet filed its Form 10-K for the period ended December 31, 2022, meaning that the Company no longer complies with Nasdaq Listing Rule 5250(c)(1).

PLx Pharma Inc. Receives Nasdaq Delisting Notice

PLx Pharma (NASDAQ: PLXP ) stock is taking a beating on Tuesday and there's a couple of reasons investors will want to know about its fall. First off, traders will keep in mind that PLXP stock underwent a massive rally on Monday.

Why Is PLx Pharma (PLXP) Stock Down 38% Today?

Agrify

GlucoTrack Inc

Can these tips help you make money with penny stocks in 2023? The post Spotting Winning Penny Stocks: 3 Top Tips  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Spotting Winning Penny Stocks: 3 Top Tips

PLx Pharma Inc. (NASDAQ:PLXP ) Q3 2022 Earnings Conference Call November 11, 2022 8:30 AM ET Company Participants Natasha Giordano - President, Chief Executive Officer Rita O'Connor - Chief Financial Officer Asif Ali - Preventative Cardiologist Janet Barth - Vice President, Investor Relations Conference Call Participants Leland Gershell - Oppenheimer Jason Butler - JMP Securities Operator Ladies and gentlemen, thank you for standing by and welcome to PLx Pharma's third quarter 2022 earnings conference call. At this time, all participants are in a listen-only mode.

PLx Pharma (PLXP) Q3 2022 Earnings Call Transcript

PLx Pharma, Inc. (PLXP) delivered earnings and revenue surprises of 15.91% and 35.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

PLx Pharma, Inc. (PLXP) Reports Q3 Loss, Misses Revenue Estimates

- Significant Reduction in Operating Expenses

PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update

SPARTA, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as “VAZALORE®”), today announced that it will release its third quarter 2022 financial results before the open of the U.S. financial markets on Friday, November 11, 2022.

PLx Pharma Inc. to Report Third Quarter 2022 Financial Results on November 11, 2022, and Provide Business Update

Legendary Baseball Pitcher and Avid Golfer Uses VAZALORE® 325 mg for Fast, Effective Pain Relief Legendary Baseball Pitcher and Avid Golfer Uses VAZALORE® 325 mg for Fast, Effective Pain Relief

Baseball Legend John Smoltz Featured on PLx Pharma's Social Channels

PLx Pharma Inc. (NASDAQ:PLXP ) Q2 2022 Earnings Conference Call August 12, 2022 8:30 AM ET Company Participants Janet Barth - Vice President, Investor Relations & Corporate Communications Natasha Giordano - President & Chief Executive Officer Rita O'Connor - Chief Financial Officer & Head, Manufacturing & Supply Chain Asif Ali - Preventative Cardiologist Conference Call Participants Jason Butler - JMP Securities Leland Gershell - Oppenheimer Elliot Wilbur - Raymond James Operator Hello, ladies and gentlemen. Thank you for standing by and welcome to the PLx Pharma Second Quarter 2022 Earnings Conference Call.

PLx Pharma Inc. (PLXP) CEO, Natasha Giordano on Q2 2022 Results - Earnings Call Transcript

PLx Pharma, Inc. (PLXP) delivered earnings and revenue surprises of 7.14% and 86.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

PLx Pharma, Inc. (PLXP) Reports Q2 Loss, Lags Revenue Estimates

Results of National Patient Experience Survey Show 95% Satisfaction Rate

Survey: Cardiovascular Patients on Aspirin Therapy Prefer VAZALORE® 81 mg

- Initiates Evaluation of Strategic Alternatives to Enhance Stockholder Value

PLx Pharma Inc. Reports Second Quarter 2022 Results and Provides Business Update

SPARTA, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as “VAZALORE®”), today announced that it will release its second quarter 2022 financial results before the open of the U.S. financial markets on Friday, August 12, 2022.

PLx Pharma Inc. to Report Second Quarter 2022 Financial Results August 12, 2022, and Provide Business Update

VAZALORE Featured in Prominent Publication as Promising Alternative to Current Aspirin Options for Secondary Prevention of Cardiac Events VAZALORE Featured in Prominent Publication as Promising Alternative to Current Aspirin Options for Secondary Prevention of Cardiac Events

PLx Pharma Inc. Showcases VAZALORE at The Annual Meeting of The Society for Cardiovascular Angiography and Interventions

PLx Pharma Inc. (NASDAQ:PLXP ) Q1 2022 Earnings Conference Call May 13, 2022 8:30 AM ET Company Participants Natasha Giordano - President, Chief Executive Officer Rita O'Connor - Chief Financial Officer Mike Valentino - Executive Chairman Asif Ali - Preventative Cardiologist Janet Barth - Vice President, Investor Relations Conference Call Participants Leland Gershell - Oppenheimer Elliot Wilbur - Raymond James Jason Butler - JMP Securities Operator Ladies and gentlemen, thank you for standing by and welcome to PLx Pharma's first quarter 2022 earnings conference call. At this time, all participants are in a listen-only mode.

PLx Pharma (PLXP) CEO, Natasha Giordano on Q1 2022 Results - Earnings Call Transcript

PLx Pharma, Inc. (PLXP) delivered earnings and revenue surprises of 4.35% and 11.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

PLx Pharma, Inc. (PLXP) Reports Q1 Loss, Lags Revenue Estimates

BUILDING A SOLID BASE OF VAZALORE ® USERS

PLx Pharma Inc. Reports First Quarter 2022 Results and Provides Business Update

SPARTA, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as “VAZALORE®”), today announced that it will release its 2022 first quarter financial results before the opening of the U.S. financial markets on Friday, May 13, 2022. Company executives will host a conference call at 8:30am ET that day with institutional investors and analysts to provide an overview of PLx Pharma's performance for the quarter, along with a business update.

PLx Pharma Inc. to Discuss 2022 First Quarter Financial Results on May 13, 2022 Conference Call and Provide Business Update

PLx Pharma Inc. (PLXP) CEO Natasha Giordano on Q4 2021 Results - Earnings Call Transcript

Dipexium Pharmaceuticals, Inc. (PLXP) delivered earnings and revenue surprises of -5.80% and 17.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Dipexium Pharmaceuticals, Inc. (PLXP) Reports Q4 Loss, Misses Revenue Estimates

Momentum Building for Novel Vazalore ® Liquid-Filled Aspirin Capsules

PLx Pharma Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update

SPARTA, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as “VAZALORE®”), today announced that Natasha Giordano, President and CEO of PLx Pharma Inc. and Rita O'Connor, Chief Financial Officer & Head of Manufacturing & Supply Chain, will present on March 15, 2022, at Oppenheimer & Co's 32nd Annual Healthcare Conference, which will be a virtual event this year.

PLx Pharma Inc. to Present at Oppenheimer & Co's 32nd Annual Healthcare Conference on March 15, 2022

SPARTA, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as “VAZALORE®”), today announced that it will release its 2021 fourth quarter financial results before the opening of the U.S. financial markets on Friday, March 11, 2022. Company executives will host a conference call at 8:30am ET that day with institutional investors and analysts to provide an overview of PLx Pharma's performance for the quarter, along with a business update.

News for PLx Pharma Stock (PLXP)